Skip to main content

Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselectiveβ-blocker

Digestive Diseases and Sciences volume 41, pages 1722–1726 (1996)Cite this article

Abstract

Terlipressin (Glypressin), a vasopressin analog, may be administered to patients with cirrhosis receiving aβ-adrenergic antagonist. Since terlipressin alone andβ-blockers alone both decrease portal pressure, a combination of these substances may have additional portal hypotensive effects. However, the negative side effects of terlipressin may be accentuated by long-termβ-blockade. Thus, the present study examined hemodynamic and metabolic responses to terlipressin in 12 patients receiving nonselectiveβ-blockers (propranolol or nadolol). Hemodynamics and oxygen (O2) -derived variables were measured prior to and 30 min after the administration (intravenous bolus) of terlipressin (1 to 2 mg, according to body weight). The hepatic venous pressure gradient and azygos blood flow significantly decreased (from 15.3±1.1 to 12.5±1.1 mm Hg, and from 0.6±0.1 to 0.5±0.1 liters/min, respectively). Arterial and pulmonary wedged pressures significantly increased. Heart rate, cardiac index, and O2 consumption were not significantly affected by terlipressin. In conclusion, in patients with cirrhosis being treated with a nonselectiveβ-blocker, terlipressin administration decreased portal pressure. Moreover, terlipressin induced only mild systemic hemodynamic effects in these patients. These results suggest that terlipressin can be administered in patients receiving aβ-adrenergic blocker.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Valla D, Lee SS, Moreau R, Hadengue A, Sayegh R, Lebrec D: Effets de la glypressine sur les circulations splanchnique et systémique des malades atteints de cirrhose. Gastroenterol Clin Biol 9:877–880, 1985

    PubMed  Google Scholar 

  2. Merkel C, Gatta A, Bolognesi M, Finucci G, Battaglia G, Angeli P, Zuin R: Hemodynamic changes of systemic, hepatic and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Dig Dis Sci 33:1103–1109, 1988

    PubMed  Google Scholar 

  3. Lin HC, Tsai YT, Lee FY, Chang TT, Wang SS, Lay CS, Lee SD, Lo KJ: Systemic and portal hemodynamic changes following triglycyllysine vasopressin plus nitroglycerin administration in patients with hepatitis B-related cirrhosis. J Hepatol 10:370–374, 1990

    PubMed  Google Scholar 

  4. Moreau R, Soubrane O, Hadengue A, Sogni P, Gaudin C, Kleber G, Lebrec D: Effets hémodynamiques de l'administration de terlipressine seule ou associée à la nitroglycérine chez les malades atteints de cirrhose. Gastroenterol Clin Biol 16:680–686, 1992

    PubMed  Google Scholar 

  5. Lebrec D, Moreau R, Cailmail S, Sogni P, Oberti F, Hadengue A: Effects of terlipressin on hemodynamics and oxygen content in conscious portal vein stenosed and cirrhotic rats receiving propranolol. J Hepatol 17:102–107, 1993

    PubMed  Google Scholar 

  6. Moreau R, Hadengue A: Prise en charge des hémorragies digestives hautes chez les malades atteints de cirrhose.In Actualités en réanimation et urgences. Paris, Arnette, 1994, pp 55–66

    Google Scholar 

  7. Lebrec D, Hillon P, Munoz C, Goldfarb G, Nouel O, Benhamou JP: The effect of propranolol on portal hypertension in patients with cirrhosis: A hemodynamic study. Hepatology 2:523–527, 1982

    PubMed  Google Scholar 

  8. Hillon P, Lebrec D, Munoz C, Jungers M, Goldfarb G, Benhamou JP: Comparison of the effects of a cardioselective and a nonselectiveβ-blocker on portal hypertension in patients with cirrhosis. Hepatology 2:528–531, 1982

    PubMed  Google Scholar 

  9. Calès P, Braillon A, Girod C, Lebrec D: Acute effect of propranolol on splanchnic circulation in normal and portal hypertensive rats. J Hepatol 1:349–357, 1985

    PubMed  Google Scholar 

  10. Moreau R, Lee SS, Hadengue A, Ozier Y, Sicot C, Lebrec D: Relationship between oxygen transport and oxygen uptake in patients with cirrhosis: Effects of vasoactive drugs. Hepatology 9:427–432, 1989

    PubMed  Google Scholar 

  11. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649, 1973

    PubMed  Google Scholar 

  12. Valla D, Bercoff E, Menu Y, Bataille C, Lebrec D: Discrepancy between wedged hepatic venous pressure and portal venous pressure after acute propranolol administration in patients with alcoholic cirrhosis. Gastroenterology 86:1400–1403, 1984

    PubMed  Google Scholar 

  13. Braillon A, Calès P, Jiron MI, Lebrec D: Estimation du débit sanguin des anastomoses porto-caves supérieures par la mesure du débit sanguin azygos chez les malades atteints de cirrhose alcoolique. Gastroenterol Clin Biol 8:47–51, 1984

    PubMed  Google Scholar 

  14. Moreau R, Hadengue A, Soupison T, Mamzer MF, Kirstetter P, Saraux JL, Assous M, Roche-Sicot J, Sicot C: Arterial and mixed venous acid-base status in patients with cirrhosis. Influence of liver failure. Liver 13:20–24, 1993

    PubMed  Google Scholar 

  15. Ezzat WR, Lautt WW: Hepatic arterial pressure-flow autoregulation is adenosine mediated. Am J Physiol 252:H836-H845, 1987

    PubMed  Google Scholar 

  16. Mastai R, Bosch J, Navasa M, Kravetz D, Bruix J, Viola C, Rodès J: Effects of alpha-adrenergic stimulation on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis. J Hepatol 4:71–79, 1987

    PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. From the Laboratoire d'Hémodynamique Splanchnique, Unité de Recherches de Physiopathologie Hépatique, INSERM U-24, and Service d'Hépatologie, Hôpital Beaujon, Clichy, France

    Florence Vachiery MD,  Richard Moreau MD,  Adrian Gadano MD, Song Yang MD, Phillippe Sogni MD, Antoine Hadengue MD, Stephane Cailmail, Thierry Soupison MD & Didier Lebrec MD

Authors
  1. Florence Vachiery MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Moreau MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adrian Gadano MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Song Yang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Phillippe Sogni MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Antoine Hadengue MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stephane Cailmail
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Thierry Soupison MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Didier Lebrec MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported in part by Ferring S.A.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Vachiery, F., Moreau, R., Gadano, A. et al. Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselectiveβ-blocker. Digest Dis Sci 41, 1722–1726 (1996). https://doi.org/10.1007/BF02088736

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02088736

Key words

  • portal hypertension
  • vasoconstrictor
  • terlipressin